Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v21-FR Version v19-FR
Language French French
Date Updated 2022-01-31 2021-12-03
Drug Identification Number 02439379 02439379
Brand name ROPIVACAINE HYDROCHLORIDE INJECTION, USP ROPIVACAINE HYDROCHLORIDE INJECTION, USP
Common or Proper name Ropivacaine Hydrochloride Injection, USP 2 mg/mL freeflex® Bag 100 mL Ropivacaine Hydrochloride Injection, USP 2 mg/mL freeflex® Bag 100 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients ROPIVACAINE HYDROCHLORIDE ROPIVACAINE HYDROCHLORIDE
Strength(s) 2MG 2MG
Dosage form(s) SOLUTION SOLUTION
Route of administration EPIDURAL INFILTRATION INFILTRATION EPIDURAL EPIDURAL INFILTRATION INFILTRATION EPIDURAL
Packaging size 100 mL 100 mL
ATC code N01BB N01BB
ATC description ANESTHETICS, LOCAL ANESTHETICS, LOCAL
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date 2021-09-22 2021-09-22
Actual start date 2021-09-22 2021-09-22
Estimated end date 2021-12-31 2021-12-31
Actual end date 2021-10-01
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Allocations will be increased to cover 100% of the 100ml demand plus 50% of the 200ml demand on a 2:1 conversion ratio. For example, 2 vials of 100ml = 1 vial of 200ml. Allocations will be increased to cover 100% of the 100ml demand plus 50% of the 200ml demand on a 2:1 conversion ratio. For example, 2 vials of 100ml = 1 vial of 200ml.
Health Canada comments